IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X, Wang CQ, Fuentes-Duculan J, Hartmann N, Peters T, Koroleva I, Hillenbrand R, Letzkus M, Yu X, Li Y, Glueck A, Hasselberg A, Flannery B, Suárez-Fariñas M, Hueber W.
Krueger JG, et al. Among authors: hasselberg a.
J Allergy Clin Immunol. 2019 Sep;144(3):750-763. doi: 10.1016/j.jaci.2019.04.029. Epub 2019 May 24.
J Allergy Clin Immunol. 2019.
PMID: 31129129
Free article.
Clinical Trial.